Business Daily Media

The Times

.

AbbVie and Eisai Announce an approval for additional indication of HUMIRA

  • Written by ACN Newswire - Press Releases

AbbVie and Eisai Announce an approval for additional indication of HUMIRA

TOKYO, Nov 27, 2020 - (JCN Newswire) - AbbVie GK and Eisai Co., Ltd. today announced an approval of additional indication of HUMIRA (generic name: adalimumab [recombinant], hereafter "HUMIRA"), a fully human anti-TNFalpha monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter "PG"). HUMIRA was granted orphan drug designation

Read more //?#

Click Frenzy returns with a free EOFY sale event for retailers this month

New owners Gabby and Hezi Leibovich bring back Australia’s leading ecommerce sales event with Australia Post as Major Sponsor   Click Frenzy is ...

The 95 Per Cent Failure Rate Is Not An AI Problem

Most Australian SMEs I speak with are already having a go at AI. Some are running formal pilots, others have a team member quietly experimenting o...

New AR tech helping to solve field service skills crisis

AI-enabled augmented reality (AR) smart glasses are emerging as a new practical solution to fill a shortage of field service technicians maintaini...

For Midsize Companies, Global Payroll Systems Matter More to Business-Security Than You Think

When a midsize company expands across borders, its payroll operation becomes exponentially more complex. These organisations typically face a new ...

GEO and the AI search shift reshaping Australian and New Zealand business visibility

For years, one of the biggest digital marketing questions for businesses was ‘how do we get onto page one of Google?’ That question still matters, ...

Why self-service is reshaping fleet management for modern businesses

Fleet management today is constrained by fragmented systems and heavy administrative demands. A lot of the work still relies on booking vehicles and...